A new study suggests that people with Alzheimer’s on the drug risperidone, an antipsychotic drug often prescribed as the brand name Risperdal, may be better off continuing to take the drug if they have not experienced negative side effects.
Because of the potential side effects, risperidone is only recommended to be prescribed for three to six months. After that point, a written explanation is required to continue the drug. A study, published in the New England Journal of Medicine and funded by the National Institutes of Health, investigated the effects of discontinuing the medication among individuals who had seen improvements as a result of the drug. Researchers prescribed risperidone to individuals with Alzheimer’s disease who showed signs of agitation and aggression. After 16 weeks, researchers put half of the individuals who did well on the drug on a placebo. The other half continued the treatment. The study found that those on the placebo were twice as likely to have their symptoms return. The rate of side effects and death were equal among the two groups.
Researchers warned that antipsychotics can carry the risk of serious side effects and should not be used on all individuals with Alzheimer’s disease, but discontinuing medication that has achieved benefits is not always the right choice. "One must be cautious about discontinuing the medication,” said study author Dr. D.P. Devanand, director of the division of geriatric psychiatry at Columbia Psychiatry and the New York State Psychiatric Institute in New York City. “If a person does well on it and there are not too many side effects, maybe they should stay on it for a while and be monitored closely."
For more information, read the article: Some With Alzheimer's Better Off Staying on Antipsychotics: Study Or, read the full study: Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease.
Audits, Managed Risk, Risk Management
ALFA recently published the 2014 Top Ten Deficiency Report, which provides a state-by-state assessment of the most common regulatory citations in seni...
Clinical Quality and Quality Care Delivery, Partnerships, Strategy
The senior living industry has an opportunity to work collaboratively with hospitals, especially as it relates to post-acute care for older adults, wr...
Facts and Figures, Health and Wellness, Managed Risk, Memory Care Best Practices and Research, Reports
Scientists have found evidence of the amyloid protein found in Alzheimer’s disease in the brains of people as young as 20. Amyloid is normal in the br...
ALFA recently submitted a statement for the record related to a hearing on financial exploitation of seniors before a U.S. Senate committee, outlining...
cheatsheet, Disabilities, End of Life, Facts and Figures, Health and Wellness, Memory Care Best Practices and Research, Memory Care Education, Reports
A new report from the Alzheimer’s Association focusing on the financial impact of Alzheimer’s disease in the United States cautions that costs could s...
Federal Agency Activity, Managed Risk
The Centers for Medicare & Medicaid Services has revised some guidance to nursing facilities, now requiring hands-on practice and in-person skills ass...
Two departments of the Administration on Community Living are working on a project to build a national training, technical assistance, and resource ce...
Early onset Alzheimer’s disease is in the spotlight with the new movie “Still Alice.” The film is raising awareness of Alzheimer’s disease, although i...
End of Life, Falls Prevention, Health and Wellness, Managed Risk
Researchers analyzed data among individuals age 65 and over and found an 8 percent increase in falls, or about a 30 percent rise in falls, from 1998-2...
End of Life, Facts and Figures, Hospice, Medicare, Partnerships, Reports
Medicare payments for hospice care in assisted living communities has more than doubled in five years, totaling $2.1 billion in 2012, according to a n...